Local and systemic host defense mechanisms against Candida: Immunopathology of candidal infections

Pediatric Infectious Disease Journal

Volumn 16, Issue 8, 1997, Pages 795-801

  Maródi, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Candida infections; Defense mechanisms; Immunopathology

Indexed keywords

ARTICLE; CANDIDA; CANDIDIASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; PRIORITY JOURNAL;

ANIMALS; CANDIDIASIS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; PEROXIDASE; PHAGOCYTES; RECOMBINANT PROTEINS;

EID: 0343580518     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199708000-00012     Document Type: Article

References (80)

1. Sternberg S. The emerging fungal threat. Science 1994;266: 1632-4.
2. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection: II. Nonbacterial infections. J Pediatr 1991;120:845-57.
3. Armstrong D. Problems in management of opportunistic fungal diseases. Rev Infect Dis 1989;11(Suppl 7):1591-9.
4. Lehrer RT, Stiehm ER, Fischer TJ, Young LS. Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med 1978;89:91-106.
5. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11: 379-90.
6. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
7. Johnston RB Jr, Neumans SL. Chronic granulomatous disease. Pediatr Clin North Am 1977;24:365-71.
8. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
9. Saxen H, Virtanen M, Carlson P, et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J 1995;14:776-81.
10. Lemieux C, St. Germain G, Vincelette J, et al. Collaborative evaluation of antigen detection by a commercial latex agglutination test and enzyme immunoassay in the diagnosis of invasive candidiasis. J Clin Microbiol 1990;28:249-53.
11. Walsh TJ, Hathorn JW, Sobel JD, et al. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991;324: 1026-31.
12. Wong B, Brauer KL. Enantioselective measurement of fungal D-arabinitol in the sera of normal adults and patients with candidiasis. 1998;26:1670-4.
13. van Deventer AJM, Goessens WHF, van Belkum A, et al. Improved detection of Candida albicans by PCR in blood of neutropenic mice with systemic candidiasis. J Clin Microbiol 1995;33:625-8.
14. Saag M, Dismukes WE. Azole agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.
15. Walsh TJ, Pizzo PA. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988;7:460-75.
16. Graybill JR, Drutz DJ. Therapeutic agents: systemic fungul infections: diagnosis and treatment. Infect Dis Clin North Am 1988;2:805-6.
17. Walsh TJ, Lee JW, Roilides E, et al. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis 1992;14(Suppl 1):139-47.
18. Cross JT, Hickerson SL, Yamauchi T. Antifungal drugs. Pediat Rev 1995;16:123-9.
19. Mathaba LT, Davies G, Warmington JR. The genotypic relationship of Candida albicans strains isolated from the oral cavity of patients with denture stomatitis. J Med Microbiol 1995;42:372-9.
20. Locci R, Peters G, Pulverer G. Microbial colonization of prosthetic devices: IV. Scanning electron microscopy of intravenous catheters invaded by yeasts. Zentralbl Bacteriol Microbiol Hyg 1981;173:419-24.
21. Johnston PG, Lee J, Domanski M, et al. Late recurrent Candida endocarditis. Chest 1991;99:1531-3.
22. Darouiche RO, Hamill RJ, Musher DM, et al. Periprosthetic candidal infections following arthroplasty. Rev Infect Dis 1989;11:89-96.
23. Mahieu HF, Rosingh HJ, Saene RKFV, Schutte HK. Deterioration of voice prosthesis by fungal vegetations [Letter]. Arch Otolaryngol 1985;111:280.
24. Odds FC. Candida and candidosis. London: Balliere Tindall, 1988:45-61.
25. Kimura LH, Pearsall NN. Adherence of Candida albicans to human buccal epithelial cells. Infect Immun 1978;21:64-8.
26. Calderone RA, Lehrer N, Segal E. Adherence of Candida albicans to buccal and vaginal epithelial cells: ultrastructural observations. Can J Microbiol 1984;30:1001-7.
27. Vecchiarelli A, Bistoni F, Cenci E, et al. In vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. J Med Vet Mycol 1985;23:377-87.
28. Diamond RD, Krzesicki R, Jao W. Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum. J Clin Invest 1978;61:349-59.
29. Heidenreich F, Dierich MP. Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun 1985;50:598-600.
30. Gustafson KS, Vercellotti GM, Bendel CM, Hostetter MK. Molecular mimicry in Candida albicans: role of an integrin analogue in adhesion of yeast to human endothelium. J Clin Invest 1991;87:1896-902.
31. Bendel CM, Hostetter MK. Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. J Clin Invest 1993;92:1840-9.
32. Ollert MW, Wende C, Görlich M, et al. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995;33:2543-9.
33. Neely AN, Law EJ, Holder IA. Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymes. Infect Immun 1986;52:200-4.
34. Neely AN, Holder IA. Effect of proteolytic activity on virulence of Candida albicans in burned mice. Infect Immun 1990;58:1527-31.
35. Jensen J, Warner T, Johnson C, Balish E. Oral immunization of mice against candidiasis. J Infect Dis 1996;174:133-40.
36. Xu-Amato J, Aicher WK, Taguchi T, et al. Selective induction of Th2 cells in murine Peyer's patches by oral immunization. Int Immunol 1992;4:433-45.
37. Owen RL, Jones AL. Epithelial cell specialisation within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974;66:89-95.
38. Scicchitano R, Stanisz A, Ernst PB, Bienenstock J. A common mucosal immune system revisited. In: Husband AJ, ed. Migration and homing of lymphoid cells. vol 2. Boca Raton, FL: CRC Press, 1988:1-34.
39. Elson CO, Weiserbs DB, Ealding W, Mackelski E. T helper cell activity in intestinal lamina propria. Ann NY Acad Sci 1983;409:230-6.
40. McGhee JR, Mestecky J, Elson CO, Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 1989;9:175-80.
41. Lacasse M, Fortier C, Chakir J, et al. Acquired resistance and persistence of Candida albicans following oral candidiasis in the mouse: a model of the carrier state in humans. Oral Microbiol Immunol 1993;8:313-8.
42. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-92.
43. Maródi L, Korchak HM, Johnston RB Jr. Mechanisms of host defense against Candida species: I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 1991; 146:2783-9.
44. Dobozy A, Szolnoky Gy, Gyulai R et al. Mannose receptors are implicated in the Candida albicans killing activity of epidermal cells. Acta Microbiol Immunol Hung 1996;43:93-5.
45. Jensen J, Warner T, Balish E, et al. Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages. J Infect Dis 1993;167:912-9.
46. Ernst PB, Clark DA, Rosenthal KL, Befus AD, Bienenstock J. Detection and characterization of cytotoxic T lymphocyte precursors in the murine intestinal intraepithelial leukocyte population. J Immunol 1986;136:2121-9.
47. Kalo A, Segal E, Sahar E, Dayan D. Interaction of Candida albicans with genital mucosal surfaces: involvement of fibronectin in adherence. J Infect Dis 1988;157:1253-6.
48. Knight L, Fletcher J. Growth of C. albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis 1971;123:371-7.
49. Rayfield EJ, Ault MA, Keusch GT, et al. Infection and diabetes: the case for glucose control. Am J Med 1982;72:439-50.
50. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study on the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315:1455-8.
51. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22: S89-94.
52. Strobel W, Krakauer R, Klaeveman HL, et al. Secretory component deficiency: a disorder of the IgA immune system. N Engl J Med 1976;294:351-6.
53. Di George AM. A new concept of the cellular basis of immunity. J Pediatr 1965;67:907-8.
54. Shyur A, Hill HR. Immunodeficiency in the 1990s. Pediatr Infect Dis J 1991;10:595-611.
55. Kirkpatrick CH, Rich RR, Benett JE. Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Intern Med 1971;74:955-78.
56. Cantorna MT, Balish E. Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun 1991;59:2447-55.
57. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:1S.
58. Whelan WL, Kirsch DR, Kwon-Chung KJ, et al. Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel hypervirulent strain. J Infect Dis 1990;162:513-8.
59. Lopez E, Aterman K. Intrauterine infection by Candida. Am J Dis Child 1968;115:663-70.
60. Schwartz DA, Reef S. Candida albicans placentitis and funisitis: early diagnosis of congenital candidemia by histopathologic examination of umbilical cord vessels. Pediatr Infect Dis J 1990;9:661-5.
61. Klotz SA, Drutz DJ, Zajic JE. Factors governing adherence of Candida species to plastic surfaces. Infect Immun 1985;55: 97-101.
62. Rotrosen D, Calderone RA, Edwards JE. Adherence of Candida species to host tissues and plastic surfaces. Rev Infect Dis 1986;8:73-85.
63. Scherer S, Stevens DA. Candida albicans dispersed, repeated gene family and its epidemiological applications. Proc Natl Acad Sci USA 1988;85:1452-6.
64. Fox BC, Mobley HT, Wade JT. The use of a DNA probe for epidemiological studies of candidiasis in immunocompromised hosts. J Infect Dis 1989;159:488-94.
65. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992;14(Suppl 1):37-42.
66. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease. Am J Med 1981;71:59-66.
67. Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969;2:135-42.
68. Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am 1988;2:135-47.
69. Maródi L, Forehand JR, Johnston RB Jr. Mechanisms of host defense against Candida species: II. Biochemical basis for killing of Candida by mononuclear phagocytes. J Immunol 1991;146:2790-4.
70. Maródi L, Káposzta R, Campbell DE, Polin RA, Csongor J, Johnston RB Jr. Candidacidal mechanisms in the human neonate: impaired IFN-gamma activation of macrophages in newborn infants. J Immunol 1994;153:5643-9.
71. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol 1989;143:671-7.
72. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991;78:907-13.
73. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl 2):18-22.
74. Maródi L, Schreiber S, Anderson D, et al. Enhancement of macrophage candidacidal activity by IFN-gamma: increased phagocytosis, killing and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 1993;91: 2596-601.
75. Romani L, Mencacci L, Tonetti R, et al. Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol 1994;24:909-13.
76. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-5.
77. Moguilevsky N, Garcia-Quintana L, Jacquet A, et al. Secretion of enzymatically active human recombinant myeloperoxidase by Chinese hamster ovary cells. Eur J Biochem 1991; 197:605-14.
78. Lefkowitz SS, Gelderman MP, Lefkowitz DL, et al. Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. J Infect Dis 1996;173: 1202-7.
79. Tournay C, Courtoy PJ, Maródi L, et al. Uptake of recombinant myeloperoxidase, free or fused to Fcγ, by macrophages enhances killing activity toward micro-organisms. DNA Cell Biol 1996;15:617-24.
80. Maródi L, Káposzta R, Moguilevsky N. Enhancement of macrophage candidacidal capacity by recombinant human myeloperoxidase and intravenous immunoglobulin. In: Kazatchkine MD, Morell A, eds. Intravenous Immunoglobulin research and therapy. New York: Parthenon 1996:348-9.